retatrutide glp-1 gip glucagon Scott Isaacs on X: "#retatrutide is a novel triple agonist peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to # Retatrutide (GLP-1/GIP/Glucagon) – 30mg -

Buford, L

Key Takeaway 3 Medical supervision is essential when using weight loss injections

Tirzepatide represents a significant advancement in obesity and diabetes treatment, as it acts as a dual agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors[1]

Because Retatrutide targets three separate receptor pathways, GLP-1, GIP, and glucagon, individual responses vary more than with single-mechanism compounds like Semaglutide, which is one reason generic charts cannot substitute for provider-directed dosing

These strategies not only illustrate the depth and breadth of pharmaceutical research but also signify the frontier of future medical innovations

Some clinics prescribe them together to target both cellular energy and growth hormone optimization simultaneously